The FDA has approved a manually injected, single-dose, prefilled epinephrine syringe (Symjepi – Adamis/Sandoz) for emergency treatment of anaphylaxis. The new device is approved in 0.3- and 0.15-mg strengths for treatment of patients weighing ≥30 kg and 15 to 30 kg, respectively; only the 0.3-mg strength is currently available. According to Sandoz, Symjepi will be made available first to institutions and later to the retail market.
EPINEPHRINE AUTO-INJECTORS — EpiPen and EpiPen Jr, which are also available generically, have been used effectively for treatment of anaphylaxis...
Since 2008, because of safety concerns, the FDA has mandated long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes.1 Reductions in the incidence of macrovascular complications in these trials with some sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists in patients at risk for cardiovascular disease (see Table 1) have led to new recommendations.2-4
STANDARD TREATMENT — Metformin (Glucophage, and others) is the drug of choice for initial treatment of type 2 diabetes.5 For patients who do not achieve their A1C goal with metformin, the choice of an additional drug varies with the ...
